Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cystatin-SA (CST2) is a secreted member of the type 2 cystatin family of cysteine protease inhibitors, found abundantly in human saliva, tears, and seminal plasma[1][2][3][5]. It plays an important role in inhibiting thiol (cysteine) proteases, thereby contributing to tissue protection and homeostasis in secretory fluids. While CST2 is not considered a classical drug target or receptor, altered expression has been implicated in modulating cell growth and drug sensitivity in certain cancers, such as increased sensitivity of gastric cancer cells to oxaliplatin via the PI3K/AKT pathway[6]. There are currently no known pharmaceuticals that directly target CST2, and its principal biological function remains natural protease inhibition in extracellular environments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cystatin-SA (CST2).